(1) Incorporate IL28B genotyping and genotype-guided therapy into the standard treatment protocol for chronic hepatitis C virus infection(2) Develop a clinical WGS sequencing program.(3) Genetic risk score to identify patients for AAA screening. This evidence concerns the gene IFNL3 and triple-A syndrome.